AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36343030
Drug: Intravascular irradiation
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular irradiation of blood (ILIB) combined with myofunctional exercises; active application of ILIB performed twice a week for 8 weeks.
Trial: 36343030
Drug: Placebo ILIB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ILIB combined with myofunctional exercises; application of placebo ILIB and an orofacial myofunctional therapy (MFT) exercise protocol.
Trial: 32673619
Drug: therapy with
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: therapy with retreat possibility with conspecifics
Trial: 32673619
Drug: therapy with
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: therapy with retreat possibility without conspecifics
Trial: 32673619
Drug: therapy without
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: therapy without retreat possibility
Trial: 33711782
Drug: pooled-dose MF/IND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pooled-dose MF/IND
Trial: 33711782
Drug: pooled-dose MF
RxNorm normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pooled-dose MF
Trial: 33711782
Drug: pooled-dose MF/IND/GLY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pooled-dose MF/IND/GLY
Trial: 33711782
Drug: medium-dose MF/IND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medium-dose MF/IND
Trial: 33711782
Drug: high-dose MF/IND/GLY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose MF/IND/GLY
Trial: 32862676
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - two doses of 50 ml 0.9% saline IV
Trial: 35293030
Drug: apalutamide 240
RxNorm normalized name: apalutamide 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apalutamide 240 mg
Trial: 35129040
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg LN18178
Trial: 35129040
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg LN18178
Trial: 35025025
Drug: Cefiderocol 2
RxNorm normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cefiderocol 2 g, 3-h infusion, q8h for 7-14 days
Trial: 35317821
Drug: Flexible low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Flexible low-dose antagonist (0.25 mg every other day, adjusted to 0.25 mg daily based on LH levels)
Trial: 35317821
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose antagonist
Trial: 33356418
Drug: Four courses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four courses of chemotherapy (including high-dose Ara-C)
Trial: 33356418
Drug: Three courses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three courses of chemotherapy
Trial: 36215323
Drug: Monthly dihydroartemisinin‐piperaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly dihydroartemisinin‐piperaquine (DP)
Trial: 32350175
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of L-carnitine (LC)
Trial: 32350175
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of L-carnitine (LC) + 30 mg of CoQ10
Trial: 33151597
Drug: Conventional non-GLP-1-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional non-GLP-1-based therapy
Trial: 35577602
Drug: 15 U
RxNorm normalized name: vitamin E 15 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 U Ultra Rapid Lispro (URLi) administered subcutaneously into the upper arm
Trial: 35577602
Drug: 15 U
RxNorm normalized name: vitamin E 15 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 U Ultra Rapid Lispro (URLi) administered subcutaneously into the thigh
Trial: 35577602
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) bolus administration of Ultra Rapid Lispro (URLi)
Trial: 32896294
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (1000 mg ferric carboxymaltose in 100 mL normal saline, infusion over 15 min)
Trial: 32896294
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 mL normal saline, infusion over 15 min)
Trial: 38296290
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron
Trial: 35939921
Drug: Oral antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipsychotics (OAPs)
Trial: 32511682
Drug: Antibiotic prescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prescribing at visits that met criteria (205 out of 214 visits, 96%)
Trial: 32511682
Drug: Antibiotic prescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prescribing at visits that did not meet criteria (193 out of 211 visits, 92%)
Trial: 35040920
Drug: 5-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day antibiotic treatment
Trial: 35040920
Drug: 10-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day antibiotic treatment
Trial: 36067389
Drug: Health problem
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health problem (e.g., hypertension)
Trial: 36067389
Drug: Healthy state
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy state (e.g., normal blood pressure)
Trial: 33941098
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 ?g/kg) for 10 min before surgery infusion (Group D)
Trial: 33941098
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion for 10 min before surgery (Group S)
Trial: 35550679
Drug: 2000 IU
RxNorm normalized name: D 2000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU daily vitamin D3 for 12 weeks
Trial: 35550679
Drug: 60,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60,000 IU weekly for 3 weeks
Trial: 35550679
Drug: 60,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60,000 IU weekly for 6 weeks
Trial: 35322981
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (5 mL)
Trial: 35176844
Drug: Sinecatechins 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinecatechins 10% ointment applied 3 times daily for 4 months after cryotherapy
Trial: 33895598
Drug: Welcome Basket
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Welcome Basket peer support intervention (1–2 sessions pre-discharge and weekly for a month post-discharge)
Trial: 34448177
Drug: Educational program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational program (4 sessions at weekly intervals)
Trial: 37417644
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (Stratacel silicone gel)
Trial: 33413702
Drug: Low RF
RxNorm normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low RF (300 mg)
Trial: 33413702
Drug: Medium RF
RxNorm normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium RF (600 mg)
Trial: 32449530
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for 6 weeks)
Trial: 35199165
Drug: gD‐2 HSV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gD‐2 HSV vaccine adjuvanted with ASO4
Trial: 35199165
Drug: Neutralizing antibodies
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing antibodies to HSV-1
Trial: 35199165
Drug: Neutralizing antibodies
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing antibodies to HSV-2
Trial: 35869682
Drug: TCI started
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TCI started with TBC set at 2.2 μg/ml
Trial: 35869682
Drug: TCI started
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TCI started with TBC set at 2.6 μg/ml
Trial: 33430924
Drug: Placebo 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 350 mg b.i.d.
Trial: 34247392
Drug: Dopaminergic antagonist
RxNorm normalized name: Dopaminergic antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic antagonist
Trial: 35422003
Drug: Peer-supported instant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer-supported instant messaging service (IMS) intervention in addition to standard diabetes therapy for 7 months
Trial: 35422003
Drug: Standard diabetes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diabetes therapy
Trial: 36057629
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without added supplementation.
Trial: 36057629
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with 250 ml fruit smoothie.
Trial: 35253334
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg/day
Trial: 33569732
Drug: Se‐NP (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Se‐NP (1 mg/kg diet)
Trial: 33569732
Drug: Se/Zn‐NP (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Se/Zn‐NP (1 mg/kg Se‐NP and 10 mg/kg Zn‐NP)
Trial: 33052762
Drug: Mindfulness-Informed Intervention
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindfulness-Informed Intervention (MII) consisting of mindfulness training with cognitive, behavioral, and psychoeducational components, delivered in four 2-hour sessions weekly
Trial: 32585738
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day milnacipran
Trial: 34709582
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg
Trial: 36254907
Drug: Nebulized normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized normal saline (NS) along with intravenous (IV) antibiotics
Trial: 35421369
Drug: Nintedanib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib (150 mg or 200 mg twice daily for 12 weeks)
Trial: 35970518
Drug: UMEC/VI 62.5/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMEC/VI 62.5/25 μg
Trial: 35245227
Drug: Frankincense essential
RxNorm normalized name: FRANKINCENSE 30 g in 30 mL TOPICAL OIL [Frankincense Essential]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frankincense essential oil applied to the soles of the feet twice a day for 2 days before, during, and 2 days after chemotherapy.
Trial: 36411403
Drug: MomsTalkShots (educational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MomsTalkShots (educational videos tailored to vaccine intentions, attitudes, and demographics)
Trial: 33403525
Drug: Partial/complete response
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial/complete response of distant disease to chemotherapy
Trial: 36919444
Drug: Active repetitive
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active repetitive transcranial magnetic stimulation treatment for 4 weeks
Trial: 34490741
Drug: GIP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIP infusion (4 pmol/kg/min)
Trial: 39557109
Drug: Warfarin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin + placebo
Trial: 32567234
Drug: NPWT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPWT with instillation of polyhexamethylene biguanide solution
Trial: 32567234
Drug: Standard NPWT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard NPWT without instillation therapy
Trial: 34606551
Drug: 165 mg
RxNorm normalized name: aspirin 165 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 165 mg GHES with 387 mg GTC
Trial: 32439492
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of anti-B19 IgM and IgG antibodies
Trial: 33846990
Drug: Meloxicam (MLX)
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meloxicam (MLX) - IM administration
Trial: 33846990
Drug: Meloxicam (MLX)
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meloxicam (MLX) - Oral administration
Trial: 33846990
Drug: Carprofen (CRP)
RxNorm normalized name: Carprofen
DrugBank: Carprofen (DB00821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carprofen (CRP) - IM administration
Trial: 33846990
Drug: Carprofen (CRP)
RxNorm normalized name: Carprofen
DrugBank: Carprofen (DB00821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carprofen (CRP) - Oral administration
Trial: 33846990
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid (TA) - IM administration
Trial: 33846990
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid (TA) - Oral administration
Trial: 34255049
Drug: WMP+Rx (Weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WMP+Rx (Weight Management Program combined with Antiobesity Medication)
Trial: 35669487
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (1200 mg calcium + 800 IU vitamin D3 daily)
Trial: 33461754
Drug: Intravenous 100
RxNorm normalized name: immune globulin intravenous 100 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 100 μg carbetocin
Trial: 35938545
Drug: Bipolar Androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bipolar Androgen Therapy (BAT)
Trial: 38632892
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT)
Trial: 32324888
Drug: Itacitinib 200
RxNorm normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib 200 mg once daily plus corticosteroids
Trial: 32324888
Drug: Itacitinib 300
RxNorm normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib 300 mg once daily plus corticosteroids
Trial: 32324888
Drug: Itacitinib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib (both doses)
Trial: 33272091
Drug: Heparin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin infusion (maximum of 20,000 units for 24 hours)
Trial: 33272091
Drug: Heparin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin infusion vs No heparin infusion
Trial: 35705501
Drug: Cenobamate (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate (target dose 300 mg/day; min/max 50/400 mg/day)
Trial: 35263841
Drug: Granisetron transdermal
RxNorm normalized name: Granisetron Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron transdermal system (GTS)
Trial: 34168648
Drug: 4-drug empiric
RxNorm normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-drug empiric standard TB treatment
Trial: 33081449
Drug: N-acetylcysteine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine at a dose of 2000 mg per day for 60 days
Trial: 33128535
Drug: Lung rehabilitation
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung rehabilitation therapy in combination with routine nursing (observation group)
Trial: 33128535
Drug: Lung rehabilitation
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung rehabilitation therapy (observation group)
Trial: 34325885
Drug: Eplerenone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (100 mg-200 mg)
Trial: 35463059
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa oil (2 g/day)
Trial: 33288923
Drug: Chimeric hemagglutinin-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric hemagglutinin-based vaccines (live-attenuated followed by inactivated vaccine)
Trial: 33288923
Drug: Placebo (intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intranasal followed by intramuscular)
Trial: 33288923
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice intramuscular)
Trial: 39534593
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (SS)
Trial: 35049127
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of intervention
Trial: 36333954
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic Acid (5 mg intravenously)
Trial: 32725695
Drug: Blood Flow
RxNorm normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood Flow Restriction (BFR) treatment
Trial: 32725695
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no BFR treatment)
Trial: 33297893
Drug: Intravenous argatroban
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous argatroban (100 µg/kg bolus followed by 3 µg/kg/min for 12 h)
Trial: 33297893
Drug: Intravenous eptifibatide
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous eptifibatide (135 µg/kg bolus followed by 0.75 µg/kg/min infusion for 2 h)
Trial: 32149759
Drug: Carbetocin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin 50 µg (C50)
Trial: 32149759
Drug: Carbetocin 100
RxNorm normalized name: Carbetocin 100 microgram/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin 100 µg (C100)
Trial: 35837833
Drug: Digoxin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.25 mg)
Trial: 35790333
Drug: Opioid analgesics
RxNorm normalized name: OPIOID ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid analgesics
Trial: 35605529
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone (XR‐NTX)
Trial: 38232249
Drug: Medication only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication only
Trial: 32350413
Drug: Sequential nab-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sequential nab-paclitaxel plus gemcitabine (SEQ)
Trial: 34406329
Drug: Office-based vergence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office-based vergence accommodative therapy (OBVAT)
Trial: 39673334
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy
Trial: 35568909
Drug: Targeted therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapies
Trial: 32777617
Drug: brief cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brief cognitive‐behavioral therapy (CBT) for suicide prevention
Trial: 35977548
Drug: Abaloparatide 80
RxNorm normalized name: ABALOPARATIDE 80MCG/0.04ML PEN 1.56ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abaloparatide 80 µg daily subcutaneous for 78 weeks
Trial: 36478476
Drug: Orismilast IR
RxNorm normalized name: Orismilast
DrugBank: Orismilast (DB19042)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orismilast IR 30 mg
Trial: 34958306
Drug: Precision SMS
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precision SMS text messages (stage-targeted educational information, next dose due date, site-specific walk-in hours)
Trial: 32545396
Drug: Ambrotose Advanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrotose Advanced (AA) at 2 or 4 g daily
Trial: 32545396
Drug: Ambrotose LIFE
RxNorm normalized name: Life-O-Gen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrotose LIFE (AL) at 2 or 4 g daily
Trial: 38916892
Drug: Sublingual buprenorphine-naloxone
RxNorm normalized name: buprenorphine / naloxone Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine-naloxone
Trial: 32115328
Drug: Anesthesiologist administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesiologist administered ACB (group 1)